Valbiotis SAS (ALVAL) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.333x

Based on the latest financial reports, Valbiotis SAS (ALVAL) has a cash flow conversion efficiency ratio of -0.333x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (€-3.92 Million ≈ $-4.58 Million USD) by net assets (€11.75 Million ≈ $13.74 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Valbiotis SAS - Cash Flow Conversion Efficiency Trend (2015–2024)

This chart illustrates how Valbiotis SAS's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ALVAL total liabilities for a breakdown of total debt and financial obligations.

Valbiotis SAS Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Valbiotis SAS ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Powercom Co Ltd
TW:3043
0.008x
Sakthi Sugars Limited
NSE:SAKHTISUG
-0.095x
Nova EYE Medical Ltd
AU:EYE
-0.144x
Delignit AG
XETRA:DLX
-0.048x
Step One Clothing Ltd
AU:STP
-0.037x
Firebird Metals Ltd
AU:FRB
-0.086x
LQwD FinTech Corp
V:LQWD
-0.022x
Inventec Besta Co Ltd
TW:8201
-0.006x

Annual Cash Flow Conversion Efficiency for Valbiotis SAS (2015–2024)

The table below shows the annual cash flow conversion efficiency of Valbiotis SAS from 2015 to 2024. For the full company profile with market capitalisation and key ratios, see Valbiotis SAS (ALVAL) market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 €10.37 Million
≈ $12.12 Million
€-11.54 Million
≈ $-13.49 Million
-1.113x -170.73%
2023-12-31 €19.60 Million
≈ $22.91 Million
€-8.06 Million
≈ $-9.42 Million
-0.411x +40.47%
2022-12-31 €13.31 Million
≈ $15.56 Million
€-9.19 Million
≈ $-10.75 Million
-0.690x -37.31%
2021-12-31 €14.23 Million
≈ $16.64 Million
€-7.16 Million
≈ $-8.37 Million
-0.503x -232.07%
2020-12-31 €7.07 Million
≈ $8.27 Million
€2.69 Million
≈ $3.15 Million
0.381x +163.19%
2019-12-31 €8.21 Million
≈ $9.60 Million
€-4.95 Million
≈ $-5.78 Million
-0.603x +1.80%
2018-12-31 €7.41 Million
≈ $8.66 Million
€-4.55 Million
≈ $-5.31 Million
-0.614x -186.99%
2017-12-31 €10.16 Million
≈ $11.88 Million
€-2.17 Million
≈ $-2.54 Million
-0.214x +90.81%
2016-12-31 €369.00K
≈ $431.40K
€-858.00K
≈ $-1.00 Million
-2.325x +73.80%
2015-12-31 €80.00K
≈ $93.53K
€-710.00K
≈ $-830.06K
-8.875x --

About Valbiotis SAS

PA:ALVAL France Packaged Foods
Market Cap
$25.61 Million
€21.91 Million EUR
Market Cap Rank
#24293 Global
#396 in France
Share Price
€0.93
Change (1 day)
-0.54%
52-Week Range
€0.55 - €1.23
All Time High
€10.54
About

Valbiotis SA engages in the research and development of dietary supplements to prevent metabolic and cardiovascular diseases in France. The company offers Lipridrivea for the treatment of hypercholesterolemia. It develops TOTUM-63 for the reduction of fasting blood glucose and treatment of type 2 diabetes; TOTUM-854, which is in Phase II/III clinical trials for reducing systolic blood pressure; a… Read more